Abstract
Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo. This study aimed to compare the efficacy of apremilast in combination therapy with narrowband (NB)-UVB versus placebo and NB-UVB treatment for repigmentation in patients with nonsegmental vitiligo. This was a 52-week prospective randomized placebo-controlled study. Adult patients with vitiligo participated. Group A received, in addition to phototherapy, apremilast at the label dosage, and group B received placebo. After 24 weeks, patients who responded (decreased Vitiligo Area Scoring Index >30%) were rerandomized to receive apremilast or placebo, combined with twice-weekly NB-UVB for 24 additional weeks. Main outcome and measure: The primary outcome measure was the comparison between the two groups of the Vitiligo Area Scoring Index score at 24 weeks. Eighty patients were randomized (40 in each group). After 24 weeks, the mean Vitiligo Area Scoring Index score decreased from 23.63 to 19.49 (P= 0.011) in the apremilast+ UVB group and from 21.57 to 15.25 (P < 0.0001) in the placebo+ UVB group. The difference between the two groups was not statistically significant (P= 0.18). No statistically significant differences were observed between the two groups after an additional 24 weeks of treatment. Apremilast does not bring any benefit to NB-UVB for treating vitiligo.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
